EGFR is targetable using tyrosine kinase inhibitors (TKIs) that bind to the active site and prevent downstream signaling, and first-generation TKIs are clinically approved for first-line treatment for lung cancers with known EGFR mutations15,16. This evidence concerns the gene EGFR and lung carcinoma.